These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

226 related items for PubMed ID: 8904135

  • 1. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T, Ishikawa H, Hashimoto I.
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
    Imanaka H, Kitahara T, Yoshinaga M, Miyata K.
    J Chemother; 1995 Nov; 7 Suppl 4():131-3. PubMed ID: 8904133
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Once-a-day therapy of cefpodoxime proxetil for respiratory tract infections.
    Sawae Y, Ninomiya K, Sumida I, Inoue T, Takaki K, Okada K, Kumagai Y, Ishimaru T, Shimono N, Misumi H.
    J Chemother; 1995 Nov; 7 Suppl 4():134-6. PubMed ID: 8904134
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Clinical evaluation of cefpodoxime proxetil in otorhinolaryngological infections].
    Takeuchi H, Ikoma H, Suzuki T, Nakajima M, Kouzaki Y, Ishizu Y, Makino H, Sugihara S, Ootawara S, Asagi K.
    Jpn J Antibiot; 1994 Jan; 47(1):84-92. PubMed ID: 8114275
    [Abstract] [Full Text] [Related]

  • 12. [Comparative trial of the clinical efficacy and tolerance of cefatrizine (Cefaperos) and cefpodoxime proxetil (Orelox) in superinfections of chronic obstructive bronchopneumopathies in adults in urban practice].
    Brambilla C, Benhamou D, Guérin JC, Kelkel E, Muir JF, Prud'homme A, Taytard A, Fauche A.
    Pathol Biol (Paris); 1995 Nov; 43(9):815-24. PubMed ID: 8746104
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten.
    Schatz BS, Karavokiros KT, Taeubel MA, Itokazu GS.
    Ann Pharmacother; 1996 Mar; 30(3):258-68. PubMed ID: 8833562
    [Abstract] [Full Text] [Related]

  • 17. [Respiratory tract infections in general practice. Cefpodoxime proxetil in patients with risk factors and concomitant illnesses].
    Kardos P, Wiese K.
    MMW Fortschr Med; 2000 Feb 03; 142(5):41. PubMed ID: 10715939
    [No Abstract] [Full Text] [Related]

  • 18. [Reevaluation of current antimicrobials. Cefpodoxime proxetil. Discussion].
    Jpn J Antibiot; 1995 Feb 03; 48(2):183-90. PubMed ID: 7745807
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections.
    Cox CE, Graveline JF, Luongo JM.
    Drugs; 1991 Feb 03; 42 Suppl 3():41-50. PubMed ID: 1726207
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.